Literature DB >> 23508358

Central nervous system involvement in the animal model of myodystrophy.

Clarissa M Comim1, Bruna P Mendonça, Diogo Dominguini, Andreza L Cipriano, Amanda V Steckert, Giselli Scaini, Mariz Vainzof, Emílio L Streck, Felipe Dal-Pizzol, João Quevedo.   

Abstract

Congenital muscular dystrophies present mutated gene in the LARGE mice model and it is characterized by an abnormal glycosylation of α-dystroglycan (α-DG), strongly implicated as having a causative role in the development of central nervous system abnormalities such as cognitive impairment seen in patients. However, the pathophysiology of the brain involvement remains unclear. Therefore, the objective of this study is to evaluate the oxidative damage and energetic metabolism in the brain tissue as well as cognitive involvement in the LARGE((myd)) mice model of muscular dystrophy. With this aim, we used adult homozygous, heterozygous, and wild-type mice that were divided into two groups: behavior and biochemical analyses. In summary, it was observed that homozygous mice presented impairment to the habituation and avoidance memory tasks; low levels of brain-derived neurotrophic factor (BDNF) in the prefrontal cortex, hippocampus, cortex and cerebellum; increased lipid peroxidation in the prefrontal cortex, hippocampus, striatum, and cerebellum; an increase of protein peroxidation in the prefrontal cortex, hippocampus, striatum, cerebellum, and cortex; a decrease of complex I activity in the prefrontal cortex and cerebellum; a decrease of complex II activity in the prefrontal cortex and cerebellum; a decrease of complex IV activity in the prefrontal cortex and cerebellum; an increase in the cortex; and an increase of creatine kinase activity in the striatum and cerebellum. This study shows the first evidence that abnormal glycosylation of α-DG may be affecting BDNF levels, oxidative particles, and energetic metabolism thus contributing to the memory storage and restoring process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23508358     DOI: 10.1007/s12035-013-8415-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  37 in total

1.  A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera.

Authors:  B P HUGHES
Journal:  Clin Chim Acta       Date:  1962-09       Impact factor: 3.786

Review 2.  BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis.

Authors:  Clive R Bramham; Elhoucine Messaoudi
Journal:  Prog Neurobiol       Date:  2005-06       Impact factor: 11.685

3.  Lipid peroxidation in brain homogenates: the role of iron and hydroxyl radicals.

Authors:  B Halliwell; J M Gutteridge
Journal:  J Neurochem       Date:  1997-09       Impact factor: 5.372

4.  A rapid PCR method for genotyping the Large(myd) mouse, a model of glycosylation-deficient congenital muscular dystrophy.

Authors:  Claudia A Browning; Prabhjit K Grewal; Christopher J Moore; Jane E Hewitt
Journal:  Neuromuscul Disord       Date:  2005-05       Impact factor: 4.296

5.  On reagents that convert cytochrome oxidase from an inactive to an active coupling state.

Authors:  D E Green; M Fry
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

Review 6.  Antioxidants, oxidative stress, and degenerative neurological disorders.

Authors:  R A Floyd
Journal:  Proc Soc Exp Biol Med       Date:  1999-12

7.  Effects of chronic mild stress on the oxidative parameters in the rat brain.

Authors:  Giancarlo Lucca; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Francieli Vuolo; Fabrícia Petronilho; Felipe Dal-Pizzol; Elaine C Gavioli; João Quevedo
Journal:  Neurochem Int       Date:  2009-01-08       Impact factor: 3.921

8.  Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport.

Authors:  A Cassina; R Radi
Journal:  Arch Biochem Biophys       Date:  1996-04-15       Impact factor: 4.013

9.  Spatial memory deficits in middle-aged mice correlate with lower exploratory activity and a subordinate status: role of hippocampal neurotrophins.

Authors:  N Francia; F Cirulli; F Chiarotti; A Antonelli; L Aloe; E Alleva
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

10.  Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.

Authors:  Cheryl Longman; Martin Brockington; Silvia Torelli; Cecilia Jimenez-Mallebrera; Colin Kennedy; Nofal Khalil; Lucy Feng; Ravindra K Saran; Thomas Voit; Luciano Merlini; Caroline A Sewry; Susan C Brown; Francesco Muntoni
Journal:  Hum Mol Genet       Date:  2003-09-09       Impact factor: 6.150

View more
  4 in total

1.  Behavioral Responses in Animal Model of Congenital Muscular Dystrophy 1D.

Authors:  Clarissa M Comim; Aryadnne L Schactae; Jaime A Soares; Letícia Ventura; Viviane Freiberger; Francielle Mina; Diogo Dominguini; Mariz Vainzof; João Quevedo
Journal:  Mol Neurobiol       Date:  2014-12-03       Impact factor: 5.590

2.  Effects of low-intensity training on the brain and muscle in the congenital muscular dystrophy 1D model.

Authors:  Clarissa M Comim; Jaime A Soares; Adriano Alberti; Viviane Freiberger; Letícia Ventura; Paula Dias; Aryadnne L Schactae; Leoberto R Grigollo; Amanda V Steckert; Daniel F Martins; Rudy J Nodari Junior; Mariz Vainzof; João Quevedo
Journal:  Neurol Sci       Date:  2022-02-19       Impact factor: 3.307

3.  Dystroglycan binding to α-neurexin competes with neurexophilin-1 and neuroligin in the brain.

Authors:  Carsten Reissner; Johanna Stahn; Dorothee Breuer; Martin Klose; Gottfried Pohlentz; Michael Mormann; Markus Missler
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

Review 4.  The roles of dystroglycan in the nervous system: insights from animal models of muscular dystrophy.

Authors:  Alec R Nickolls; Carsten G Bönnemann
Journal:  Dis Model Mech       Date:  2018-12-19       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.